| Qurat-ul-ain Jelani, MD | |
|
1 Northeast Dr, Bangor, ME 04401-4332 | |
| (207) 275-3800 | |
| (207) 275-3836 |
| Full Name | Qurat-ul-ain Jelani |
|---|---|
| Gender | Female |
| Speciality | Interventional Cardiology |
| Experience | 20 Years |
| Location | 1 Northeast Dr, Bangor, Maine |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427311711 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Eastern Maine Medical Center | Bangor, ME | Hospital |
| Millinocket Regional Hospital | Millinocket, ME | Hospital |
| Mayo Regional Hospital | Dover foxcroft, ME | Hospital |
| Penobscot Valley Hospital | Lincoln, ME | Hospital |
| Cary Medical Center | Caribou, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Acadia Hospital Corp. | 7719878495 | 80 |
| Charles A. Dean Memorial Hospital | 1557279031 | 19 |
| Eastern Maine Medical Center | 2062315161 | 577 |
News Archive
Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.
University of Michigan Medical School physicians and scientists earned more than $366 million in National Institutes of Health research funding in federal fiscal year 2009, according to NIH data. In all, the School's faculty brought in more than $435 million in research funding from all sources in U-M fiscal year 2009.
INTEGRA has expanded the range of interchangeable pipetting heads for its market-leading handheld VIAFLO 96/384 electronic pipettes.
Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced publication of the BLISS-52 study of BENLYSTA in autoantibody-positive patients with active systemic lupus erythematosus in The Lancet.
› Verified 1 days ago
| Entity Name | Eastern Maine Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790789147 PECOS PAC ID: 2062315161 Enrollment ID: O20040128000088 |
News Archive
Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.
University of Michigan Medical School physicians and scientists earned more than $366 million in National Institutes of Health research funding in federal fiscal year 2009, according to NIH data. In all, the School's faculty brought in more than $435 million in research funding from all sources in U-M fiscal year 2009.
INTEGRA has expanded the range of interchangeable pipetting heads for its market-leading handheld VIAFLO 96/384 electronic pipettes.
Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced publication of the BLISS-52 study of BENLYSTA in autoantibody-positive patients with active systemic lupus erythematosus in The Lancet.
› Verified 1 days ago
| Entity Name | Penobscot Valley Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093716086 PECOS PAC ID: 8426942889 Enrollment ID: O20040209000635 |
News Archive
Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.
University of Michigan Medical School physicians and scientists earned more than $366 million in National Institutes of Health research funding in federal fiscal year 2009, according to NIH data. In all, the School's faculty brought in more than $435 million in research funding from all sources in U-M fiscal year 2009.
INTEGRA has expanded the range of interchangeable pipetting heads for its market-leading handheld VIAFLO 96/384 electronic pipettes.
Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced publication of the BLISS-52 study of BENLYSTA in autoantibody-positive patients with active systemic lupus erythematosus in The Lancet.
› Verified 1 days ago
| Entity Name | Acadia Hospital Corp. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215940523 PECOS PAC ID: 7719878495 Enrollment ID: O20040323000136 |
News Archive
Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.
University of Michigan Medical School physicians and scientists earned more than $366 million in National Institutes of Health research funding in federal fiscal year 2009, according to NIH data. In all, the School's faculty brought in more than $435 million in research funding from all sources in U-M fiscal year 2009.
INTEGRA has expanded the range of interchangeable pipetting heads for its market-leading handheld VIAFLO 96/384 electronic pipettes.
Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced publication of the BLISS-52 study of BENLYSTA in autoantibody-positive patients with active systemic lupus erythematosus in The Lancet.
› Verified 1 days ago
| Entity Name | Eastern Maine Healthcare Systems Inland Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376579557 PECOS PAC ID: 6305817503 Enrollment ID: O20040802001656 |
News Archive
Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.
University of Michigan Medical School physicians and scientists earned more than $366 million in National Institutes of Health research funding in federal fiscal year 2009, according to NIH data. In all, the School's faculty brought in more than $435 million in research funding from all sources in U-M fiscal year 2009.
INTEGRA has expanded the range of interchangeable pipetting heads for its market-leading handheld VIAFLO 96/384 electronic pipettes.
Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced publication of the BLISS-52 study of BENLYSTA in autoantibody-positive patients with active systemic lupus erythematosus in The Lancet.
› Verified 1 days ago
| Entity Name | Maine Coast Regional Health Facilities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740249739 PECOS PAC ID: 1052208113 Enrollment ID: O20040804001405 |
News Archive
Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.
University of Michigan Medical School physicians and scientists earned more than $366 million in National Institutes of Health research funding in federal fiscal year 2009, according to NIH data. In all, the School's faculty brought in more than $435 million in research funding from all sources in U-M fiscal year 2009.
INTEGRA has expanded the range of interchangeable pipetting heads for its market-leading handheld VIAFLO 96/384 electronic pipettes.
Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced publication of the BLISS-52 study of BENLYSTA in autoantibody-positive patients with active systemic lupus erythematosus in The Lancet.
› Verified 1 days ago
| Entity Name | Blue Hill Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023057809 PECOS PAC ID: 7911991336 Enrollment ID: O20080312000055 |
News Archive
Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.
University of Michigan Medical School physicians and scientists earned more than $366 million in National Institutes of Health research funding in federal fiscal year 2009, according to NIH data. In all, the School's faculty brought in more than $435 million in research funding from all sources in U-M fiscal year 2009.
INTEGRA has expanded the range of interchangeable pipetting heads for its market-leading handheld VIAFLO 96/384 electronic pipettes.
Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced publication of the BLISS-52 study of BENLYSTA in autoantibody-positive patients with active systemic lupus erythematosus in The Lancet.
› Verified 1 days ago
| Entity Name | Charles A. Dean Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659388213 PECOS PAC ID: 1557279031 Enrollment ID: O20100608000349 |
News Archive
Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.
University of Michigan Medical School physicians and scientists earned more than $366 million in National Institutes of Health research funding in federal fiscal year 2009, according to NIH data. In all, the School's faculty brought in more than $435 million in research funding from all sources in U-M fiscal year 2009.
INTEGRA has expanded the range of interchangeable pipetting heads for its market-leading handheld VIAFLO 96/384 electronic pipettes.
Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced publication of the BLISS-52 study of BENLYSTA in autoantibody-positive patients with active systemic lupus erythematosus in The Lancet.
› Verified 1 days ago
| Entity Name | Mrh Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558319103 PECOS PAC ID: 1355770892 Enrollment ID: O20200803002384 |
News Archive
Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.
University of Michigan Medical School physicians and scientists earned more than $366 million in National Institutes of Health research funding in federal fiscal year 2009, according to NIH data. In all, the School's faculty brought in more than $435 million in research funding from all sources in U-M fiscal year 2009.
INTEGRA has expanded the range of interchangeable pipetting heads for its market-leading handheld VIAFLO 96/384 electronic pipettes.
Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced publication of the BLISS-52 study of BENLYSTA in autoantibody-positive patients with active systemic lupus erythematosus in The Lancet.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Qurat-ul-ain Jelani, MD 43 Whiting Hill Rd Ste 300, Brewer, ME 04412-1006 Ph: (207) 973-5000 | Qurat-ul-ain Jelani, MD 1 Northeast Dr, Bangor, ME 04401-4332 Ph: (207) 275-3800 |
News Archive
Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.
University of Michigan Medical School physicians and scientists earned more than $366 million in National Institutes of Health research funding in federal fiscal year 2009, according to NIH data. In all, the School's faculty brought in more than $435 million in research funding from all sources in U-M fiscal year 2009.
INTEGRA has expanded the range of interchangeable pipetting heads for its market-leading handheld VIAFLO 96/384 electronic pipettes.
Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced publication of the BLISS-52 study of BENLYSTA in autoantibody-positive patients with active systemic lupus erythematosus in The Lancet.
› Verified 1 days ago
Eddy Karnabi, MD PHD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Northeast Dr, Bangor, ME 04401 Phone: 207-275-3800 | |
Dr. Theodore William James, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 417 State St Ste 121, Bangor, ME 04401 Phone: 207-973-4266 | |
Fnu Kaleemullah, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 489 State St, Bangor, ME 04401 Phone: 207-973-7314 | |
Sverrir I Gunnarsson, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Northeast Dr, Bangor, ME 04401 Phone: 207-275-3800 | |
Liga Yusvirazi, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 360 Broadway, Bangor, ME 04401 Phone: 207-907-3283 | |
Ilsa Annetta Shulman, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 900 Broadway, Bangor, ME 04401 Phone: 207-907-3300 Fax: 207-907-1923 | |
Dr. Michael Paul Sighinolfi, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 360 Broadway Ste 100, Bangor, ME 04401 Phone: 207-907-3550 Fax: 207-907-3562 |